Steve saw the future as a bright and boundless place, lit the path forward, and inspired us to follow. We miss you, my friend.

@EurRadiology @GIBI230 @GVAsanitat @incliva_iis @GVAclinic @QuibimBiomarker 👏Thanks to all the collaborators of this multicenter study: @alfarocervello @mapibafe @CrisMonton @doctorbenlloch @ajimenez_pastor @aalberich @GIBI230 @QuibimBiomarker @medicina_uv @incliva_iis @UCSD @GVAsanitat

A radiomics-based artificial intelligence model to assess the risk of relapse in localized colon cancer in @ESMO_Open. A new “Risk Stratification”score based on clinical/pathological and radiomics features outperforming conventional methods. https://t.co/3Vq6edoOeV

The 13th @EsurOffice prostate MRI course is being held today in Cambridge. We are grateful that our team can hear directly from radiologists and oncologists to help us better understand their challenges, refine our solutions and make a meaningful contribution to #ProstateCancer.

👏Enhorabuena @QuibimBiomarker 🏆Quibim, que cuenta con #ApoyofinancieroIVF, ha sido galardonada en los premios otorgados en la 27ª Noche de las Telecomunicaciones Valencianas. 🫂La consellera @GVAhisenda @rut_merino fue la encargada de hacer entrega de este reconocimiento.

«Las centrales nucleares a pleno funcionamiento habrían hecho el apagón menos probable». Mi entrevista en @cronicaglobal https://t.co/F8epezeLnH

El presidente del Gobierno, @sanchezcastejon, miente sobre las centrales nucleares o demuestra su ignorancia sobre tecnología eléctrica al acusarlas de empeorar el apagón del 28 de abril de 2025. Las centrales nucleares aportan inercia al sistema eléctrico, ayudando a evitar

🆕 @QuibimBiomarker's QP-Prostate® CAD receives FDA 510(k) clearance The company's flagship solution leverages #AI to reveal hidden aggressive prostate cancer lesions 🔬 Congrats @aalberich & team on this incredible milestone! 🎉

🏆 We’re thrilled to share that Quibim has secured 3rd place in the 50-100 employees category of Spain’s #BestWorkplaces25! This recognition by @GPTW_Spain reflects our commitment to a people-first culture and workplace well-being. A huge thank you to our incredible team—let’s

🇦🇷 MILEI’S ADVISOR: ARGENTINA EYES AI + NUCLEAR FUTURE Dr. Reidel, @dreidel1: “We want to be an AI hub—and a commercially nuclear energy country. We’ll probably be one of the first countries with a commercially available SMR solution." https://t.co/L1fQreXRcd

La valenciana @QuibimBiomarker ha obtenido la autorización en EE.UU. para su software QP-Prostate CAD, que ayuda a detectar el cáncer de próstata con IA. Un paso clave para su comercialización a escala internacional. ¡Enhorabuena, @aalberich y equipo! 👏 https://t.co/wLFpo4DUH6

🎯La innovació en el sector salut, a debat al #FòrumOcupació! 🗣 Ana Blanco Sánchez, Dir d'ajudes i innovació a QUIBIM, explica com la tecnologia està transformant el diagnòstic mèdic i la recerca en imatge biomèdica Una ponència imprescindible per entendre el futur del sector!

Why did we invest in @QuibimBiomarker? ⤵ 💪 Strong team led by @aalberich 🩻 It's transforming precision medicine with #AI imaging biomarkers 🤝 Partnerships with industry leaders in biopharma 🗃 Own medical imaging dataset: QP Insights Read more ➡ https://t.co/SHPfLcvlsa

Pasé un rato muy interesante con @aalberich hablando de cómo la IA puede ayudar (y mucho) en el diagnóstico médico. Aquí está el resultado.

6/7 I've been in the trenches long enough to know the difference between hype and real innovation. Artificial Specific Intelligence is the way forward. Cc: Build Collective companies doing it right: @plumerai @OrionisBio @QuibimBiomarker @nabla_ai @Smartex_AI

Turning medical images into actionable data- @QuibimBiomarker is using Artificial Specific Intelligence to analyze medical imaging with precision, detect disease early, and improve treatment outcomes. From detecting subtle changes in brain structure for early Alzheimer's

Exciting news! @QuibimBiomarker has closed a $50M Series A to transform medical processes with AI-powered imaging. We’re proud to support @aalberich and his team as they advance precision medicine! https://t.co/u2uhVOivB9

We're proud to be part of @QuibimBiomarker's $50 million Series A funding round 🙌 🩺 The Valencia-based company led by @aalberich, is on a mission is to turn imaging into a catalyst for precision health through #AI Read more 🔗 https://t.co/slno8qVUpN

Thrilled to announce the successful closure of our $50M Series A. This funding propels our mission to redefine #medicalimaging and transform #healthcare. Huge thanks to our team and partners—together, we’re improving health outcomes worldwide. https://t.co/rJmHPkoI2k

The #medicalimaging community has started to give its verdict on the UK government's 26-page strategy document for AI that was unveiled on 13 January. https://t.co/s1cNh0FFML #radiology #healthtech @SignifyResearch @aalberich @QuibimBiomarker